Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder

Simple item page
dc.contributor.authorStein D.J.
dc.contributor.authorCameron A.
dc.contributor.authorAmrein R.
dc.contributor.authorMontgomery S.A.
dc.date.accessioned2011-05-15T15:59:17Z
dc.date.available2011-05-15T15:59:17Z
dc.date.issued2002
dc.description.abstractSocial phobia (social anxiety disorder) is a highly prevalent and chronic disorder that is associated with significant comorbidity and disability. Despite recent advances in the pharmacotherapy of the disorder, there is a paucity of randomized controlled trials on patients with comorbid disorders and on maintenance treatment. A randomized placebo-controlled, double-blind multi-site trial of moclobemide, a reversible inhibitor of monoamine oxidase A, was undertaken with 390 subjects. After an initial 12 weeks, there was the option of continuing for an additional 6 months of treatment. The primary efficacy parameter chosen was responder status as defined by the Clinical Global Impression scale change item. From week 4 onwards, there was a significantly higher response rate on moclobemide than on placebo. Superiority of medication over placebo was similar in patients with comorbid anxiety disorders (33% of subjects) and without, as well as in patients with different subtypes of social anxiety disorder; indeed, treatment with moclobemide rather than placebo was the strongest predictor of response. Adverse events were similar across treatment groups, and were typically mild and transient. In the extension phase, response rates remained higher in the moclobemide group, and ratings of tolerability were equally high in both groups. Thus, in a large sample of social anxiety disorder patients with and without comorbid anxiety disorders, moclobemide was both effective and well-tolerated in the short as well as long-term. These data confirm and extend previous findings on the value of moclobemide in the treatment of social anxiety disorder, and strengthen the range of therapeutic options for managing this important disorder. © 2002 Lippincott Williams & Wilkins.
dc.description.versionArticle
dc.identifier.citationInternational Clinical Psychopharmacology
dc.identifier.citation17
dc.identifier.citation4
dc.identifier.issn2681315
dc.identifier.urihttp://hdl.handle.net/10019.1/11101
dc.subjectmoclobemide
dc.subjectmonoamine oxidase A inhibitor
dc.subjectplacebo
dc.subjectanxiolytic agent
dc.subjectadult
dc.subjectanxiety neurosis
dc.subjectarticle
dc.subjectclinical trial
dc.subjectcomorbidity
dc.subjectcontrolled clinical trial
dc.subjectcontrolled study
dc.subjectdouble blind procedure
dc.subjectdrug efficacy
dc.subjectdrug tolerability
dc.subjectfemale
dc.subjecthuman
dc.subjectlong term care
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectpriority journal
dc.subjectrandomized controlled trial
dc.subjectsocial phobia
dc.subjectadolescent
dc.subjectaged
dc.subjectanxiety disorder
dc.subjectcomparative study
dc.subjectdrug administration
dc.subjectmiddle aged
dc.subjectmulticenter study
dc.subjectoutpatient
dc.subjectphobia
dc.subjecttime
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAged
dc.subjectAnti-Anxiety Agents
dc.subjectAnxiety Disorders
dc.subjectComparative Study
dc.subjectDouble-Blind Method
dc.subjectDrug Administration Schedule
dc.subjectFemale
dc.subjectHuman
dc.subjectMale
dc.subjectMiddle Age
dc.subjectMoclobemide
dc.subjectOutpatients
dc.subjectPhobic Disorders
dc.subjectTime Factors
dc.subjectHumans
dc.subjectMiddle Aged
dc.titleMoclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder
dc.typeArticle
Files
Collections
Stellenbosch University - Scopus Publications